Knowledge and Encounter Research Unit, Mayo Clinic, Rochester, MN 55905, USA.
Clin Endocrinol (Oxf). 2010 Dec;73(6):777-91. doi: 10.1111/j.1365-2265.2010.03875.x.
Surgery is commonly used in the management of pituitary nonfunctioning adenomas (NFPA). The goal of this systematic review and meta-analysis is to evaluate the effect of surgery on mortality, surgical complications, pituitary function and vision.
We searched MEDLINE, EMBASE and Cochrane CENTRAL, queried experts and reviewed the reference list of included publications. Eligible studies were comparative and noncomparative longitudinal studies that enroled patients with NFPA who underwent surgery (alone or in combination with other therapies). Reviewers, working independently and in duplicate, determined study eligibility with adequate reproducibility and extracted descriptive, quality and outcome data. Risks, relative risks (RR) and 95% confidence intervals (CIs) were estimated from each study and pooled using random-effects meta-analysis.
Most included studies were uncontrolled case series in which patients received a combination of surgery and radiotherapy. The overall quality of the evidence was very low. Median follow-up was 4·29 years. When surgery was not combined with radiotherapy, there was an increased risk of tumour recurrence (RR 1·97; 95% CI, 1·15-3·35). Complications were more likely with the transcranial than with the transsphenoidal approach (mortality RR 4·89; 95% CI, 3·15-6·47; new anterior pituitary deficits RR 4·90; 95% CI, 2·94-7·82; and persistent diabetes insipidus RR 2·50; 95% CI, 1·05-5·35). Overall, transsphenoidal surgery had fairly low perioperative mortality (≤ 1%) and low complication rate (≤ 5% for all patient-important outcomes), but only less than a third of the patients had improvement in pituitary function.
Observational evidence supports the association between a combined approach of transsphenoidal surgery with radiotherapy and improvements in visual field defects and reduction in tumour recurrence.
手术常用于治疗无功能垂体腺瘤(NFPA)。本系统评价和荟萃分析的目的是评估手术对死亡率、手术并发症、垂体功能和视力的影响。
我们检索了 MEDLINE、EMBASE 和 Cochrane 中心数据库,并向专家查询和审查了纳入文献的参考文献列表。合格的研究是比较性和非比较性的纵向研究,纳入了接受手术(单独或联合其他治疗)治疗的 NFPA 患者。审查员独立且重复地确定研究的合格性,具有足够的可重复性,并提取描述性、质量和结果数据。从每项研究中估计风险、相对风险(RR)和 95%置信区间(CI),并使用随机效应荟萃分析进行汇总。
大多数纳入的研究为未对照的病例系列研究,患者接受了手术和放疗的联合治疗。证据的总体质量非常低。中位随访时间为 4.29 年。当手术不与放疗联合时,肿瘤复发的风险增加(RR 1.97;95%CI,1.15-3.35)。与经颅入路相比,经蝶窦入路发生并发症的可能性更大(死亡率 RR 4.89;95%CI,3.15-6.47;新发垂体前叶功能减退 RR 4.90;95%CI,2.94-7.82;和持续性尿崩症 RR 2.50;95%CI,1.05-5.35)。总体而言,经蝶窦手术的围手术期死亡率(≤1%)和并发症发生率(所有重要患者结局的发生率≤5%)均较低,但只有不到三分之一的患者垂体功能得到改善。
观察性证据支持经蝶窦手术联合放疗的联合方法与视野缺损改善和肿瘤复发减少之间的关联。